PMID- 35388661
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220711
IS  - 2038-8306 (Electronic)
IS  - 1121-760X (Print)
IS  - 1121-760X (Linking)
VI  - 66
IP  - 2
DP  - 2022 Apr 7
TI  - Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor 
      receptor (EGFR) expression in different breast cancer subtypes and their clinical 
      significance.
LID - 10.4081/ejh.2022.3315 [doi]
LID - 3315
AB  - Increasing evidence has shown that mammaglobin, GATA-binding protein 3 (GATA3), 
      and epithelial growth factor receptor (EGFR) have unique clinical implications 
      for breast cancer subtyping and classification, as well as for breast cancer 
      targeted therapy. It is particularly important to clarify the correlation between 
      their expression and different molecular breast carcinoma subtypes to better 
      understand the molecular basis of the subtypes and to identify effective 
      therapeutic targets for the disease. This study aimed to evaluate mammaglobin, 
      GATA3, and EGFR expression in different breast cancer subtypes, as well as their 
      clinical significance. Subjects of the study included 228 patients with breast 
      cancer at The First Affiliated Hospital of University of Science and Technology 
      of China. They were divided into triple negative (TN), Luminal A, Luminal B, and 
      HER-2 positive (HER-2.P) breast cancer groups based on molecular classification. 
      Immunohistochemical methods were used to detect mammaglobin, GATA3, and EGFR 
      expression in cases of different molecular subtypes before determining the 
      correlation between protein expression and subtype. Mammaglobin and GATA3 
      expression levels were found to significantly vary with respect to 
      histopathological grade, lymph node status, and molecular subtype; EGFR 
      expression was significantly correlated with breast cancer histopathological 
      grade and molecular subtype. For breast cancer, the expression levels of 
      mammaglobin and GATA3, as well as mammaglobin and EGFR, were significantly 
      correlated. In addition, there was a significantly negative correlation between 
      the expression levels of GATA3 and EGFR in breast cancer tissue samples, 
      especially in HER-2.P samples. These findings provide a theoretical basis for 
      assessing breast cancer clinical prognosis based on the cancer subtype, and 
      hence, have significant practical value.
FAU - Kong, Xin
AU  - Kong X
AD  - Department of Pathology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei. 
      kxin086@live.cn.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Pathology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei. 
      wq_sky@163.com.
FAU - Li, Jie
AU  - Li J
AD  - Department of Pathology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei. 
      fiona0103@yeah.net.
FAU - Li, Ming
AU  - Li M
AD  - Department of Pathology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei. 
      aylm123@163.com.
FAU - Deng, Fusheng
AU  - Deng F
AD  - Department of General Surgery, The First Affiliated Hospital of University of 
      Science and Technology of China, Hefei. dengfusheng2010@163.com.
FAU - Li, Chuanying
AU  - Li C
AD  - Department of Pathology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei. 
      lcy12224@rjh.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20220407
PL  - Italy
TA  - Eur J Histochem
JT  - European journal of histochemistry : EJH
JID - 9207930
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carrier Proteins)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (Mammaglobin A)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - *Breast Neoplasms/metabolism
MH  - Carrier Proteins/metabolism
MH  - ErbB Receptors/metabolism
MH  - Female
MH  - GATA3 Transcription Factor/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Mammaglobin A/metabolism
PMC - PMC9012142
EDAT- 2022/04/08 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/04/07
CRDT- 2022/04/07 05:36
PHST- 2021/08/06 00:00 [received]
PHST- 2022/03/31 00:00 [accepted]
PHST- 2022/04/07 05:36 [entrez]
PHST- 2022/04/08 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/04/07 00:00 [pmc-release]
AID - 10.4081/ejh.2022.3315 [doi]
PST - epublish
SO  - Eur J Histochem. 2022 Apr 7;66(2):3315. doi: 10.4081/ejh.2022.3315.